rate and inherited in autosomal recessive manner. SCD patients have vertebral anomalies with marked intrinsic rib abnormalities such as absent ribs, abnormal orientation, irregularity of shape and size, bifurcation, broadening, fusion of ribs, etc. They are often short statured, have higher survival rate, less likely to have associated neural tube defects and inherited in either autosomal recessive or autosomal dominant manner. [5] There is no definitive treatment of this syndrome and management is directed towards prevention of respiratory infection and symptomatic support. Our patient had features of STD. This syndrome may pose multiple challenges to anaesthesiologist such as difficulty in airway management, respiratory compromise and problems posed by associated anomalies. As these patients have recurrent respiratory infections, perioperative assessment and management of these complications is of prime importance. [6] Cyanosis while crying in the absence of cyanotic heart disease may be seen due to collapse of the trachea owing to the absence of tracheal cartilaginous rings. [4] Fusion of cervical vertebra and kyphoscoliosis pose a special challenge during airway management and contribute to intubation difficulty. Supraglottic airway devices can be of great help specially in centres without facility for fiberoptic intubation. [7] As we were able to intubate the patient in first go, we did not use supraglottic device. Inhalational induction is preferred as it allows intubation in spontaneously breathing patients. Pre-operative sedatives and opioid analgesics should not be used to avoid respiratory depression. We avoided the use of nitrous oxide as these patients may have associated pulmonary hypertension. [8] Post-operative mechanical ventilation may be needed because of the presence of kyphoscoliosis and decreased chest wall compliance. The perioperative morbidity and mortality of these patients is mainly related to pulmonary consequences of thoracic skeletal dysplasia and associated anomalies. Adequate care during pre-operative period, anaesthetic management and post-operative period are imperative in successful outcomes in patients with Jarcho-Levin syndrome.
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Cisatracurium degradation:
Intravenous fluid warmer the culprit?
Sir,
Cisatracurium is a non-depolarising muscle relaxant that undergoes degradation in plasma at physiological pH and temperature by organ-independent Hofmann elimination. [1] This accounts for 77% of its overall elimination. [2, 3] Its metabolites (laudanosine and a monoquaternary acrylate) do not possess any intrinsic neuromuscular blocking property. [1] Cisatracurium is not hydrolysed by plasma esterase directly. [4] It has been noted that the rate of cisatracurium degradation increases 6.5 fold with an increase in pH from 6.4 to 7.8. [4] 45 min. At this time, a small notching of the capnographic curve was noted which gradually deepened suggesting breakthrough spontaneous breathing. The surgeon too complained of abdominal tightness and patient breathing. PNS showed a return of three twitches of TOF. A bolus of 2 mg cisatracurium was administered, and its infusion rate was increased to 0.1 mg/kg/h. Neither spontaneous breathing ceased nor TOF showed any change. Infusion rate was now increased to 10 mg/h with no improvement in muscle relaxation. It was now considered that administration of cisatracurium infusion was being done via the warmed infusion line, which might be degrading it before reaching the patient. Cisatracurium infusion was now changed to the other infusion line without a warmer. Again a bolus of 2 mg cisatracurium was given and infusion continued at 0.14 mg/kg/h. Within 2 min, spontaneous breathing stopped, capnographic notching disappeared, and TOF responses were lost. Infusion rate was now brought back to 0.08 mg/kg/h. Rest of the procedure proceeded uneventfully.
The fluid warmer was kept at 38°C to compensate for a small loss of heat due to the long intravenous line. The capacity of 150 cm long intravenous extension tubing plus three-way connector was calculated to be 5 ml.
With an infusion rate of approximately 5 ml/kg/h 0.9% normal saline via this channel, cisatracurium had a transit time of about 1 min via the extension tubing. Exposure to a temperature of nearly 38°C possibly degraded cisatracurium before it reached the patient. This was evident by restoration of its activity as soon as the same syringe pumps containing cisatracurium and remifentanil were attached to the unwarmed infusion line, establishing thereby a direct relationship between temperature and cisatracurium degradation since every other variable (pH and nature of infusion) remained constant.
Possibility also exists that there might have been some degradation in cisatracurium infused via 0.9% normal saline (pH range from 4.5 to 7.0) with resultant loss of activity. Keeping this entire problem in mind and to prevent it from happening again, we would like to suggest that the capacity of 150 cm long intravenous extension tubing may be reduced from 5 ml capacity to 2 ml by employing pressure tubing for this purpose (DTXPlus © , Argon Medical Devices, The Hague, The Netherlands). In addition, the three-way connectors should always be connected near the patient end, immediately next to the cannula Any lowering of body temperature is known to prolong the duration of action of cisatracurium by slowing its metabolism. However, there is no report in the literature suggesting that there is a shortening of its activity or quality of action by enhanced metabolism when administered as an infusion via a channel at higher than body temperature. We recently observed this interesting correlation between raised temperature of the administration line (38°C) and significantly reduced neuromuscular blocking property of cisatracurium when administered via this heated infusion channel.
A 66-year-old American Society of Anesthesiologists physical status III female patient weighing 73 kg with carcinoma of rectum was posted for abdominoperineal resection. Except for well-controlled diabetes mellitus on insulin, she had no other organ dysfunction or concurrent abnormalities in terms of fluid/electrolyte imbalance or other relevant investigations.
Patient received 2.5 mg oral midazolam as premedication. Two intravenous channels were established, one on either hand, using 16 and 18 gauge catheters. Standard monitoring was started including a peripheral nerve stimulator (PNS) (Innervator Constant Current PNS NS 252 © ; Fisher and Paykel Electronics Ltd., Auckland, NZ) and invasive blood pressure. She was induced with 110 mg propofol, 75 µg fentanyl and paralysed using 10 mg cisatracurium.
Following the loss of all train of four (TOF) responses, laryngoscopy and tracheal intubation was performed. Anaesthesia was maintained with 60% nitrous oxide in oxygen, sevoflurane (1-3%), and remifentanil infusion between 200 and 400 µg/h to maintain heart rate and blood pressure within ±20% of basal value. Cisatracurium was administered as a continuous infusion at a rate of 0.08 mg/kg/h.
As per the request of the operating surgeon, both upper limbs of the patient were kept at her side. Two extension tubings (DTXPlus © , Argon Critical Care Systems, The Hague, The Netherlands) measuring 150 cm were fixed to the intravenous catheters and to their proximal ends, two three way-connectors were attached for the anaesthesiologist to administer medications or fluids as per patient's need. One of these extended intravenous infusion lines was connected to a Hotline ® fluid warmer (Smiths Medical ASD, Inc. Rockland, USA), kept at 38°C.
Anaesthesia continued uneventfully for the first to minimise mixing of the intravenous fluids with
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The successful use of sugammadex and uneventful recovery from general anaesthesia in a patient with myotonic dystrophy Sir,
Myotonic dystrophy is an autosomal dominant multisystem disorder characterised by progressive weakness and wasting of muscles, cardiomyopathy and cardiac conduction defects, restrictive lung disease, sleep apnoea syndrome, slow gastric emptying, endocrine disorders and cataracts. This condition is often associated with prolonged muscle contractions with defective relaxation (myotonia). There are two major types of myotonic dystrophy: Type 1 and type 2. These are caused by mutations in different genes. Anaesthetic management of this condition can be challenging due to the potential for these patients to develop perioperative cardiorespiratory complications and because they may demonstrate abnormal responses to sedative and neuromuscular blocking agents.
We present a report of the successful management of a 60-year-old gentleman with myotonic dystrophy type 1, weighing 70 kg, who presented for elective laparoscopic cholecystectomy. His symptoms had included progressive weakness of the upper limbs with dysarthria, soft voice and mild static swallowing impairment. He had dilated cardiomyopathy and had a pacemaker/defibrillator in situ. The patient also had moderate obstructive sleep apnoea and was saturating at 99% in room air. This patient had never undergone general anaesthesia, and all his previous investigations had been performed previously under local anaesthesia with sedation. Pre-operative examination findings included the characteristic facial features of myotonic dystrophy and a modified Mallampati class III.
On the day of surgery, no oral pre-medication was given other than his usual medications. Intra-operative monitoring included five-lead electrocardiography, pulse oximetry, capnography, invasive blood pressure monitoring with a right radial artery catheter and bispectral index (BIS). Magnet and external defibrillator pads were placed over his chest. Following adequate pre-oxygenation, induction and maintenance of anaesthesia were carried out with 0.5 mg of midazolam followed by propofol and remifentanil target controlled infusion titrated to BIS between 40 and 60 and haemodynamic status. After the initial administration of 50 mg rocuronium for intubation anticipating approximately 2 h procedure, we had planned to give subsequent doses guided by a peripheral nerve stimulator. A grade II b laryngeal view was obtained with direct laryngoscopy and a size 8.5 endotracheal tube was inserted. The maintenance phase of anaesthesia was uneventful, and no other analgesia was given intra-operatively. Upper and lower body forced air warmers were used throughout. The surgery was uncomplicated and lasted 45 min. At the end of surgery as no twitches were observed with train-of-four (TOF) stimulus after the initial intubating dose of rocuronium, the decision was made to reverse neuromuscular blockade with an initial sugammadex dose of 200 mg and further administer additional doses
